Latest Safety News

Volt Group Limited is set to acquire Perth-based 4D Delta Pty Ltd for $7.25 million, adding a profitable digital asset inspection business to its portfolio. The acquisition is supported by a $4 million capital raise and aims to accelerate Volt’s growth in technology-enabled resource services.

Chimeric Therapeutics reports promising interim results from its CHM CDH17 Phase 1/2 trial, with 75% disease control at 28 days and durable responses in gastrointestinal cancers.

NEXTDC’s FY25 Annual General Meeting reveals robust financial growth, significant data centre expansions, and enhanced funding capacity to capitalise on AI infrastructure demand.

SGH Ltd reported record earnings and reaffirmed its FY26 EBIT growth guidance at its 2025 AGM, while addressing recent workplace fatalities and outlining strategic growth initiatives.

Anteris Technologies has gained FDA approval to start patient recruitment in the US for its pivotal PARADIGM Trial, following initial European regulatory success. The company advances manufacturing and clinical readiness as it pushes toward key regulatory milestones.

Lycopodium Limited projects steady growth for FY26 with revenue guidance of $390-$410 million, underpinned by strong project momentum and the strategic SAXUM acquisition expanding its footprint in the Americas.

QMines Limited has successfully raised over $1 million through its Share Purchase Plan, aiming to accelerate exploration at its Mt Mackenzie gold and silver project. The new shares are set to be issued mid-November, marking a key step in the company’s growth strategy.

GrainCorp reported a 12.3% revenue increase to $7.31 billion in FY25, alongside record grain volumes and growth in Animal Nutrition, despite a 35% drop in statutory net profit. The company declared a fully franked 24-cent final dividend and advanced key sustainability initiatives.

Orezone Gold Corporation reported solid Q3 2025 results with strong liquidity and on-track hard rock expansion, setting the stage for a significant production boost in 2026.

Orica Limited has delivered its strongest financial performance in over a decade, driven by premium product demand and digital innovation, while advancing ambitious sustainability targets. The company signals continued growth for 2026 despite emerging supply chain challenges.

Orica Limited has reported its strongest earnings in over a decade, with a 23% rise in EBIT to $992 million and a 32% jump in net profit before significant items. The company also increased its share buy-back program and declared a higher dividend, signaling confidence in its growth strategy and sustainability commitments.

Immutep Limited’s Phase II EFTISARC-NEO trial reveals a novel immunotherapy combo delivering a striking 51.5% tumour response in soft tissue sarcoma patients, alongside robust immune activation signals.